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Durrington and colleagues have used this old
wisdom, and in this issue of the BMJ (p 1497) show that
it is indeed possible to use this approach to find new
patients.7 By testing all first degree relatives of 200
patients with familial hypercholesterolaemia they
found another 121 patients. In the general population
at least 60 000 tests would have been needed to identify
this many people with the condition. With the aid of a
nurse specialist, simple cholesterol testing, and the use
of small pedigrees Durrington and colleagues convinc-
ingly show that adopting an active approach to case
finding works for familial hypercholesterolaemia.
Other investigators, including our group in the
Netherlands, have come to similar conclusions, with two
modest differences in approach. Firstly, testing in the
Netherlands was not restricted to first degree relatives
but included everyone in the extended family. This obvi-
ously reduces the proportion of people identified as
having the disorder. On average, over a four year period
one index patient led us to 20 additional family
members, and eight new patients were identified
(unpublished data). The second and most profound dif-
ference, however, lies in the use of DNA diagnostics. If
the most sensitive test is used—namely age specific and
sex specific centiles for total and low density lipoprotein
cholesterol—16.6% of cases would have been missed and
12.5% would have been diagnosed as having familial
hypercholesterolaemia when they actually had poly-
genic hypercholesterolaemia. Hence, active screening
for a disorder requires a diagnosis that is rock solid, and
that can only be provided by using DNA testing to actu-
ally find the genetic mutation causing the disorder.
Durrington et al correctly point out that the
screening criteria developed by Wilson and Jungner
easily apply to familial hypercholesterolaemia,8 but it is
unlikely that DNA testing for the disorder has harmful
psychological consequences.9–11
We know how to organise the screening, and we
have the capacity for testing, be it for cholesterol
concentrations or DNA mutations. We also have safe
and effective treatment that can save lives and money.
Our ministries of health should not hesitate but should
support screening and treatment programmes; a few
specialised nurses working in close collaboration with
lipid clinics could work miracles.
J J P Kastelein director
Lipid Research Group, Academic Medical Center Amsterdam,
Department of Vascular Medicine, Room G1-146, Meibergdreef 9,
1105 AZ Amsterdam, the Netherlands (e.vandongen@amc.uva.nl)
1 Scientific Steering Committee on behalf of the Simon Broome Register
Group. Risk of fatal coronary heart disease in familial hypercholestero-
laemia.. BMJ 1991;303:893-6.
2 Lansberg PJ, Tuzgöl S, van de Ree MA, Defesche JC, Kastelein JJP.
Prevalentie van Familiaire Hypercholesterolemie onder volwassenen in
vier huisartsenpraktijken hoger dan werd aangenomen [Prevalence of
familial hypercholesterolemia in four general practices higher than sup-
posed]. Ned Tijdschr Geneeskd 2000;144:1437-40.
3 Scientific Steering Committee on behalf of the Simon Broome Register
Group. Mortality in treated heterozygous familial hypercholesterolaemia:
implications for clinical management. Atherosclerosis 1999;142:105-12.
4 Mol MJTM, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef
AFH. Effects of synvinolin (MK-733) on plasma lipids in familial hyperc-
holesterolaemia. Lancet 1986;ii:936-9.
5 Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent
of underdiagnosis of familial hypercholesterolaemia in routine practice:
prospective registry study. BMJ 2000;321:148-9.
6 Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In:
Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular
bases of inherited disease. 7th ed. New York: McGraw-Hill, 1995:1981-2030.
7 Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN.
Outcome of case finding among relatives of patients with known hetero-
zygous familial hypercholesterolaemia. BMJ 2000;321:1497-500.
8 Wilson JMG, Jungner G. Principles and practice of screening for disease.
Geneva: World Health Organization, 1968. (Public health paper No. 34)
9 Andersen LK, Jensen HK, Juul S, Faergeman O. Patient attitudes to
detection of heterozygous familial hypercholesterolaemia. Arch Intern
Med 1997;157:553-60.
10 Tonstad S. Familial hypercholesterolaemia: a pilot study of parents’ and
children’s concerns. Acta Paediatr 1996;85:1307-13.
11 Tonstad S, Novik TS, Vandvik IH. Psychosocial function during treatment
for familial hypercholesterolemia. Pediatrics 1996;98:249-55.
Emerging arboviral encephalitis
Newsworthy in the West but much more common in the East
The recent outbreaks of West Nile encephalitis inNew York and Israel are drawing the westernworld’s attention to the potential threat of
arthropod-borne virus (arbovirus) encephalitis.1 But in
many parts of Asia, infection with West Nile virus’s sis-
ter, Japanese encephalitis virus, is a daily reality.
Epidemics of encephalitis were described in Japan
from the 1870s onwards, and Japanese encephalitis
virus was first isolated from a fatal case in the 1930s.2
West Nile virus was isolated from the blood of a febrile
woman in Uganda a few years later in 1937.3 Both
viruses are small enveloped RNA viruses, members of
the genus Flavivirus (family Flaviviridae), named after
the prototype yellow fever virus (flavus is the Latin for
yellow). The flaviviruses are relatively new viruses,
derived from a common ancestor 10-20 000 years ago,
that are rapidly evolving to fill new ecological niches.4
Both West Nile and Japanese encephalitis virus are
transmitted in an enzootic cycle between small birds by
Culex mosquitoes, though for Japanese encephalitis
pigs are important amplifying hosts. Humans become
infected by Culex mosquitoes coincidentally, but are
not part of the natural cycle.
Although known to be widely distributed across
much of Africa, southern Europe, and the Middle East,
West Nile virus was, until recently, considered to be
relatively benign.3 It causes a non-specific febrile
illness, or a characteristic fever-arthralgia-rash syn-
drome, which occurred in large epidemics in Israel in
the 1950s and South Africa in the 1970s. Direct
invasion of the central nervous system to cause
encephalitis was thought to be a rarity. In contrast,
Japanese encephalitis virus has always been recognised
as a killer. Over the past 50 years it has spread
relentlessly across Southeast Asia, India, southern
China, and the Pacific—reaching Australia in 1998.5
Culex mosquitoes are unavoidable in rural Asia, and
almost everyone is exposed to the virus. Only about 1 in
300 infections results in disease, and there is a wide
range of presentations from a simple febrile illness to a
severe meningoencephalitis, as well as a newly
recognised polio-like acute flaccid paralysis.6 There are
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estimated to be 50 000 cases of Japanese encephalitis
annually, with 15 000 deaths. The actual numbers may
become clearer with the application of new simple rapid
diagnostic tests.7 In addition to the high mortality, about
half the survivors have severe neuropsychiatric sequelae,
with their associated socioeconomic burden.
The epidemiology of West Nile virus has also
changed in recent years. Increasing numbers of cases
of encephalitis are being seen in all areas where the
virus occurs, and during a large outbreak in Romania
in 1996, 393 patients with neurological disease had
laboratory evidence of West Nile virus infection.8 Then,
in 1999, West Nile virus reached America for the first
time. A quick-witted physician had noticed a cluster of
cases of encephalitis in the Bronx, New York. Initial
serological tests pointed to St Louis encephalitis virus
(the American sister of the neurotropic flaviviruses,
which caused encephalitis epidemics in America in the
1930s, but is not normally found this far north). How-
ever, sick birds at the Bronx zoo and crows dropping
from the sky suggested something else,9 since the local
virus would not normally cause disease in its natural
hosts. West Nile virus was isolated subsequently from
both avian and human cases.10 By the time mosquito
spraying and the arrival of winter had reduced the
population of Culex mosquitoes 62 people had
developed encephalitis and seven had died.
These recent findings in Asia and the West raise
important issues about the spread, control, and patho-
genesis of arboviral encephalitis. Many theories have
been proposed on how West Nile virus reached New
York, including illegally imported exotic birds,
airplane-borne mosquitoes, European refugees, and
even biological terrorism, but infected birds migrating
from Israel now seems the most likely.11 However it
arrived, surveillance has shown that the virus is now
well established in the region. Japanese encephalitis
virus is also thought to be spread by birds, but mosqui-
toes blown between Pacific islands may contribute too.5
Although we can do little to limit the spread of
enzootic flaviviruses, we can minimise the number of
human cases. Surveillance of mosquitoes, sentinel
birds, and dead birds for West Nile virus in America
warned of this summer’s impending outbreak.
Consequently the number of human cases was
minimised by advising people to avoid mosquito bites
and by implementing measures to reduce the
mosquito population, such as removing breeding sites
and spraying. Unfortunately such measures are
impracticable in Asia, where the rice fields in which
Culex mosquitoes breed are a mainstay of the economy.
There are no vaccines against West Nile virus yet. An
expensive formalin-inactivated and newer live attenu-
ated vaccine against Japanese encephalitis are avail-
able, but not for the majority of the 2.8 billion people
living in affected regions.12 13 For them, the factors
determining who, of all those infected with Japanese
encephalitis virus, develops neurological disease may
be critically important. The relative contributions of
the human immune response and viral strain
differences are currently being investigated.
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Research misconduct: Britain’s failure to act
Act or risk losing public confidence in research
More than a year ago the good and the great ofBritish medicine assembled in Edinburghand agreed that the time had come to act
decisively on research misconduct.1–3 Unfortunately,
nothing visible has happened. Yet the so far largely
submerged problem of research misconduct is surfac-
ing like a decomposing corpse.4 If the leaders in medi-
cine do not act they risk losing public confidence in
medical research.
Fraud in research has a long and dishonourable
history, but the problem came firmly onto the agenda
in Britain in the early 1980s.5 One consequence was a
report from the Royal College of Physicians of London
in 1991.6 Unfortunately the report was shelved. The
excuses are familiar: fraud doesn’t really matter
because science is self correcting; patients have not
been harmed; it’s very rare; existing local systems can
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